Through successful development and characterization, we have demonstrated the efficacy of ROBO1-NK cells derived from patients' own PBMCs in effectively lysing ovarian cancer cell lines, primary ovarian cancer cells, and tumor organoids. The gene discussed is ROBO1; the disease is ovarian carcinoma.